Prognostic factors and patterns of failure after surgery for T4 rectal cancer in the beyond total mesorectal excision era.
Journal
The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
07
02
2019
revised:
31
03
2019
accepted:
26
04
2019
pubmed:
25
7
2019
medline:
9
4
2020
entrez:
25
7
2019
Statut:
ppublish
Résumé
Despite advances in the rates of total mesorectal excision (TME) for rectal cancer surgery, decreased local recurrence rates and increased 5-year survival, there still exists large variation in the quality of treatment received. Up to 30 per cent of rectal cancers are locally advanced at presentation and approximately 5-10 per cent still breach the mesorectal plane and invade adjacent structures despite neoadjuvant therapy. With the evolution of extended resections for rectal cancers beyond the TME plane, proponents advocate that these resections should be performed only in specialist centres. The aim was to assess the prognostic factors and patterns of failure after beyond TME surgery for T4 rectal cancers. Data were collected from prospective databases at three high-volume institutions specializing in beyond TME surgery for T4 rectal cancers between 1990 and 2013. The primary outcome measures were overall survival, local recurrence and patterns of first failure. Three hundred and sixty patients were identified. The negative resection margin (R0) rate was 82·8 per cent (298 patients) and the local recurrence rate was 12·5 per cent (45 patients). The type of surgical procedure (Hartmann's: hazard ratio (HR) 4·49, 95 per cent c.i. 1·99 to 10·14; P = 0·002) and lymphovascular invasion (HR 2·02, 1·08 to 3·77; P = 0·032) were independent predictors of local recurrence. The 5-year overall survival rate for all patients was 61 (95 per cent c.i. 55 to 67) per cent. The 5-year cumulative incidence of first failure was 8 per cent for local recurrence, 6 per cent for local and distant disease, and 18 per cent for distant disease. This study has demonstrated that a coordinated approach in specialist centres for beyond TME surgery can offer good oncological and long-term survival in patients with T4 rectal cancers. A pesar de las mejoras en los porcentajes de extirpación total del mesorrecto (total mesorectal excision, TME) en la cirugía de cáncer de recto, la disminución de los porcentajes de recidiva local y el aumento de la supervivencia a 5 años, todavía existe una gran variabilidad en la calidad del tratamiento recibido. Hasta el 30% de los cánceres de recto están localmente avanzados en el momento del diagnóstico y aproximadamente el 5-10% sobrepasarán el plano mesorrectal e invadirán las estructuras adyacentes a pesar del tratamiento neoadyuvante. Con la evolución de las resecciones ampliadas para los cánceres de recto que sobrepasan el plano de la TME, los defensores recomiendan que estas resecciones solo se realicen en centros especializados. El objetivo fue evaluar los factores pronósticos y los patrones de recidiva después de la cirugía ampliada más allá de la TME para los cánceres de recto T4. MÉTODOS: Los datos se recogieron a partir de bases de datos prospectivas de tres instituciones de alto volumen especializadas en resecciones ampliadas más allá de la TME para el cáncer de recto T4 entre 1990 y 2013. Los criterios de valoración principal fueron la supervivencia global, la recidiva local y los patrones de la primera recidiva. Se identificaron 360 pacientes. El margen de resección fue negativo (R0) en el 82,8% (n = 298) y el porcentaje de recidiva local fue de 12,5% (n = 45). El tipo de cirugía realizada (Hartmann: cociente de riesgos instantáneos, hazard ratio, HR 4,49; i.c. del 95%: 1,99-10,14; P = 0,002) y la invasión linfovascular (HR 2,02; i.c. del 95%: 1,08-3,77; P = 0,032) fueron factores predictivos independientes de recidiva local. La supervivencia global a 5 años para todos los pacientes fue del 61% (i.c. del 95%: 55-67). La incidencia acumulada a los 5 años de la primera recidiva fue de 8% para la recidiva local, 6% para la recidiva local y a distancia, y 18% para la recidiva a distancia. CONCLUSIÓN: Este estudio demuestra que un abordaje coordinado en centros especializados para cirugía más allá de la TME puede ofrecer una buena supervivencia oncológica y a largo plazo en pacientes con cáncer de recto T4.
Sections du résumé
BACKGROUND
Despite advances in the rates of total mesorectal excision (TME) for rectal cancer surgery, decreased local recurrence rates and increased 5-year survival, there still exists large variation in the quality of treatment received. Up to 30 per cent of rectal cancers are locally advanced at presentation and approximately 5-10 per cent still breach the mesorectal plane and invade adjacent structures despite neoadjuvant therapy. With the evolution of extended resections for rectal cancers beyond the TME plane, proponents advocate that these resections should be performed only in specialist centres. The aim was to assess the prognostic factors and patterns of failure after beyond TME surgery for T4 rectal cancers.
METHODS
Data were collected from prospective databases at three high-volume institutions specializing in beyond TME surgery for T4 rectal cancers between 1990 and 2013. The primary outcome measures were overall survival, local recurrence and patterns of first failure.
RESULTS
Three hundred and sixty patients were identified. The negative resection margin (R0) rate was 82·8 per cent (298 patients) and the local recurrence rate was 12·5 per cent (45 patients). The type of surgical procedure (Hartmann's: hazard ratio (HR) 4·49, 95 per cent c.i. 1·99 to 10·14; P = 0·002) and lymphovascular invasion (HR 2·02, 1·08 to 3·77; P = 0·032) were independent predictors of local recurrence. The 5-year overall survival rate for all patients was 61 (95 per cent c.i. 55 to 67) per cent. The 5-year cumulative incidence of first failure was 8 per cent for local recurrence, 6 per cent for local and distant disease, and 18 per cent for distant disease.
CONCLUSION
This study has demonstrated that a coordinated approach in specialist centres for beyond TME surgery can offer good oncological and long-term survival in patients with T4 rectal cancers.
ANTECEDENTES
A pesar de las mejoras en los porcentajes de extirpación total del mesorrecto (total mesorectal excision, TME) en la cirugía de cáncer de recto, la disminución de los porcentajes de recidiva local y el aumento de la supervivencia a 5 años, todavía existe una gran variabilidad en la calidad del tratamiento recibido. Hasta el 30% de los cánceres de recto están localmente avanzados en el momento del diagnóstico y aproximadamente el 5-10% sobrepasarán el plano mesorrectal e invadirán las estructuras adyacentes a pesar del tratamiento neoadyuvante. Con la evolución de las resecciones ampliadas para los cánceres de recto que sobrepasan el plano de la TME, los defensores recomiendan que estas resecciones solo se realicen en centros especializados. El objetivo fue evaluar los factores pronósticos y los patrones de recidiva después de la cirugía ampliada más allá de la TME para los cánceres de recto T4. MÉTODOS: Los datos se recogieron a partir de bases de datos prospectivas de tres instituciones de alto volumen especializadas en resecciones ampliadas más allá de la TME para el cáncer de recto T4 entre 1990 y 2013. Los criterios de valoración principal fueron la supervivencia global, la recidiva local y los patrones de la primera recidiva.
RESULTADOS
Se identificaron 360 pacientes. El margen de resección fue negativo (R0) en el 82,8% (n = 298) y el porcentaje de recidiva local fue de 12,5% (n = 45). El tipo de cirugía realizada (Hartmann: cociente de riesgos instantáneos, hazard ratio, HR 4,49; i.c. del 95%: 1,99-10,14; P = 0,002) y la invasión linfovascular (HR 2,02; i.c. del 95%: 1,08-3,77; P = 0,032) fueron factores predictivos independientes de recidiva local. La supervivencia global a 5 años para todos los pacientes fue del 61% (i.c. del 95%: 55-67). La incidencia acumulada a los 5 años de la primera recidiva fue de 8% para la recidiva local, 6% para la recidiva local y a distancia, y 18% para la recidiva a distancia. CONCLUSIÓN: Este estudio demuestra que un abordaje coordinado en centros especializados para cirugía más allá de la TME puede ofrecer una buena supervivencia oncológica y a largo plazo en pacientes con cáncer de recto T4.
Autres résumés
Type: Publisher
(spa)
A pesar de las mejoras en los porcentajes de extirpación total del mesorrecto (total mesorectal excision, TME) en la cirugía de cáncer de recto, la disminución de los porcentajes de recidiva local y el aumento de la supervivencia a 5 años, todavía existe una gran variabilidad en la calidad del tratamiento recibido. Hasta el 30% de los cánceres de recto están localmente avanzados en el momento del diagnóstico y aproximadamente el 5-10% sobrepasarán el plano mesorrectal e invadirán las estructuras adyacentes a pesar del tratamiento neoadyuvante. Con la evolución de las resecciones ampliadas para los cánceres de recto que sobrepasan el plano de la TME, los defensores recomiendan que estas resecciones solo se realicen en centros especializados. El objetivo fue evaluar los factores pronósticos y los patrones de recidiva después de la cirugía ampliada más allá de la TME para los cánceres de recto T4. MÉTODOS: Los datos se recogieron a partir de bases de datos prospectivas de tres instituciones de alto volumen especializadas en resecciones ampliadas más allá de la TME para el cáncer de recto T4 entre 1990 y 2013. Los criterios de valoración principal fueron la supervivencia global, la recidiva local y los patrones de la primera recidiva.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1685-1696Informations de copyright
© 2019 BJS Society Ltd Published by John Wiley & Sons Ltd.
Références
Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery - the clue to pelvic recurrence? Br J Surg 1982; 69: 613-616.
Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 1479-1482.
MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993; 341: 457-460.
Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T et al.; Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246: 693-701.
Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 2000; 356: 93-96.
Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373: 811-820.
Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986; 2: 996-999.
Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J et al.; MRC CR07/NCIC-CTG CO16 Trial Investigators; NCRI Colorectal Cancer Study Group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009; 373: 821-828.
Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008; 26: 303-312.
Kapiteijn E, Putter H, van de Velde CJ; Cooperative investigators of the Dutch ColoRectal Cancer Group. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 2002; 89: 1142-1149.
Wibe A, Møller B, Norstein J, Carlsen E, Wiig JN, Heald RJ et al. A national strategic change in treatment policy for rectal cancer - implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 2002; 45: 857-866.
Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
Dietz DW; Consortium for Optimizing Surgical Treatment of Rectal Cancer (OSTRiCh). Multidisciplinary management of rectal cancer: the OSTRICH. J Gastrointest Surg 2013; 17: 1863-1868.
Archampong D, Borowski D, Wille-Jørgensen P, Iversen LH. Workload and surgeon's specialty for outcome after colorectal cancer surgery. Cochrane Database Syst Rev 2012; (3)CD005391.
Kreiter E, Yasui Y, de Gara C, White J, Winget M. Referral rate to oncologists and its variation by hospital for colorectal cancer patients. Ann Surg Oncol 2012; 19: 714-721.
Wexner SD, Rotholtz NA. Surgeon influenced variables in resectional rectal cancer surgery. Dis Colon Rectum 2000; 43: 1606-1627.
Monson JR, Probst CP, Wexner SD, Remzi FH, Fleshman JW, Garcia-Aguilar J et al. Failure of evidence-based cancer care in the United States: the association between rectal cancer treatment, cancer center volume, and geography. Ann Surg 2014; 260: 625-631.
Rickles AS, Dietz DW, Chang GJ, Wexner SD, Berho ME, Remzi FH et al. High rate of positive circumferential resection margins following rectal cancer surgery: a call to action. Ann Surg 2015; 262: 891-898.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30.
Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011; 29: 3753-3760.
MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 2006; 333: 779.
van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12: 575-582.
Kokelaar RF, Evans MD, Davies M, Harris DA, Beynon J. Locally advanced rectal cancer: management challenges. Onco Targets Ther 2016; 9: 6265-6272.
Quyn AJ, Austin KK, Young JM, Badgery-Parker T, Masya LM, Roberts R et al. Outcomes of pelvic exenteration for locally advanced primary rectal cancer: overall survival and quality of life. Eur J Surg Oncol 2016; 42: 823-828.
Beyond TME Collaborative. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg 2013; 100: 1009-1014.
Madoff RD. Extended resections for advanced rectal cancer. Br J Surg 2006; 93: 1311-1312.
Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349: 2117-2127.
Bhangu A, Ali SM, Brown G, Nicholls RJ, Tekkis P. Indications and outcome of pelvic exenteration for locally advanced primary and recurrent rectal cancer. Ann Surg 2014; 259: 315-322.
Gannon CJ, Zager JS, Chang GJ, Feig BW, Wood CG, Skibber JM et al. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol 2007; 14: 1870-1877.
Smith JD, Nash GM, Weiser MR, Temple LK, Guillem JG, Paty PB. Multivisceral resections for rectal cancer. Br J Surg 2012; 99: 1137-1143.
Harris DA, Davies M, Lucas MG, Drew P, Carr ND, Beynon J; Swansea Pelvic Oncology Group. Multivisceral resection for primary locally advanced rectal carcinoma. Br J Surg 2011; 98: 582-588.
Kusters M, Austin KK, Solomon MJ, Lee PJ, Nieuwenhuijzen GA, Rutten HJ. Survival after pelvic exenteration for T4 rectal cancer. Br J Surg 2015; 102: 125-131.
PelvEx Collaborative. Surgical and survival outcomes following pelvic exenteration for locally advanced primary rectal cancer: results from an international collaboration. Ann Surg 2019; 269: 315-321.
Larkin JO, O'Connell PR. Multivisceral resection for T4 or recurrent colorectal cancer. Dig Dis 2012; 30(Suppl 2): 96-101.
Heriot AG, Byrne CM, Lee P, Dobbs B, Tilney H, Solomon MJ et al. Extended radical resection: the choice for locally recurrent rectal cancer. Dis Colon Rectum 2008; 51: 284-291.
Harris CA, Solomon MJ, Heriot AG, Sagar PM, Tekkis PP, Dixon L et al. The outcomes and patterns of treatment failure after surgery for locally recurrent rectal cancer. Ann Surg 2016; 264: 323-329.
Tekkis PP, Heriot AG, Smith J, Thompson MR, Finan P, Stamatakis JD; Association of Coloproctology of Great Britain and Ireland. Comparison of circumferential margin involvement between restorative and nonrestorative resections for rectal cancer. Colorectal Dis 2005; 7: 369-374.
Wibe A, Syse A, Andersen E, Tretli S, Myrvold HE, Søreide O; Norwegian Rectal Cancer Group. Oncological outcomes after total mesorectal excision for cure for cancer of the lower rectum: anterior vs. abdominoperineal resection. Dis Colon Rectum 2004; 47: 48-58.
Phang PT, McGahan CE, McGregor G, MacFarlane JK, Brown CJ, Raval MJ et al. Effects of change in rectal cancer management on outcomes in British Columbia. Can J Surg 2010; 53: 225-231.
Russell MC, You YN, Hu CY, Cormier JN, Feig BW, Skibber JM et al. A novel risk-adjusted nomogram for rectal cancer surgery outcomes. JAMA Surg 2013; 148: 769-777.
Helewa RM, Park J. Surgery for locally advanced T4 rectal cancer: strategies and techniques. Clin Colon Rectal Surg 2016; 29: 106-113.
Yeo SG, Kim MJ, Kim DY, Chang HJ, Kim MJ, Baek JY et al. Patterns of failure in patients with locally advanced rectal cancer receiving pre-operative or post-operative chemoradiotherapy. Radiat Oncol 2013; 8: 114.
Kim Y, Kim DY, Kim TH, Kim SY, Baek JY, Kim MJ et al. Patterns of failure in rectal cancer with positive circumferential resection margin after surgery following preoperative chemoradiation: a propensity core matching analysis. Br J Radiol 2018; 91: 20180143.
Nagtegaal ID, Gosens MJ, Marijnen CA, Rutten HJ, van de Velde CJ, van Krieken JH. Combinations of tumor and treatment parameters are more discriminative for prognosis than the present TNM system in rectal cancer. J Clin Oncol 2007; 25: 1647-1650.
Gosens MJ, van Krieken JH, Marijnen CA, Meershoek-Klein Kranenbarg E, Putter H, Rutten HJ et al. Improvement of staging by combining tumor and treatment parameters: the value for prognostication in rectal cancer. Clin Gastroenterol Hepatol 2007; 5: 997-1003.
Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998; 133: 894-899.
Burton S, Brown G, Daniels IR, Norman AR, Mason B, Cunningham D; Royal Marsden Hospital, Colorectal Cancer Network. MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? Br J Cancer 2006; 94: 351-357.
Wibe A, Carlsen E, Dahl O, Tveit KM, Weedon-Fekjaer H, Hestvik UE et al.; Norwegian Rectal Cancer Group. Nationwide quality assurance of rectal cancer treatment. Colorectal Dis 2006; 8: 224-229.
Påhlman L, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjödahl R et al. The Swedish rectal cancer registry. Br J Surg 2007; 94: 1285-1292.
Jörgren F, Johansson R, Damber L, Lindmark G. Risk factors of rectal cancer local recurrence: population-based survey and validation of the Swedish rectal cancer registry. Colorectal Dis 2010; 12: 977-986.
Bokey EL, Ojerskog B, Chapuis PH, Dent OF, Newland RC, Sinclair G. Local recurrence after curative excision of the rectum for cancer without adjuvant therapy: role of total anatomical dissection. Br J Surg 1999; 86: 1164-1170.
de Chaisemartin C, Penna C, Goere D, Benoist S, Beauchet A, Julie C et al. Presentation and prognosis of local recurrence after total mesorectal excision. Colorectal Dis 2009; 11: 60-66.
Nikberg M, Chabok A, Letocha H, Kindler C, Glimelius B, Smedh K. Lymphovascular and perineural invasion in stage II rectal cancer: a report from the Swedish colorectal cancer registry. Acta Oncol 2016; 55: 1418-1424.
Umpleby HC, Fermor B, Symes MO, Williamson RC. Viability of exfoliated colorectal carcinoma cells. Br J Surg 1984; 71: 659-663.
Fermor B, Umpleby HC, Lever JV, Symes MO, Williamson RC. Proliferative and metastatic potential of exfoliated colorectal cancer cells. J Natl Cancer Inst 1986; 76: 347-349.
O'Dwyer PJ, Martin EW Jr. Viable intraluminal tumour cells and local/regional tumour growth in experimental colon cancer. Ann R Coll Surg Engl 1989; 71: 54-56.
McGregor JR, Galloway DJ, Jarrett F, Brown IL, George WD. Anastomotic suture materials and experimental colorectal carcinogenesis. Dis Colon Rectum 1991; 34: 987-992.
Gertsch P, Baer HU, Kraft R, Maddern GJ, Altermatt HJ. Malignant cells are collected on circular staplers. Dis Colon Rectum 1992; 35: 238-241.
Heah SM, Eu KW, Ho YH, Leong AF, Seow-Choen F. Hartmann's procedure vs. abdominoperineal resection for palliation of advanced low rectal cancer. Dis Colon Rectum 1997; 40: 1313-1317.
Meyer F, Marusch F, Koch A, Meyer L, Führer S, Köckerling F et al.; German Study Group Colorectal Carcinoma (Primary Tumor). Emergency operation in carcinomas of the left colon: value of Hartmann's procedure. Tech Coloproctol 2004; 8(Suppl 1): s226-s229.
Sverrisson I, Nikberg M, Chabok A, Smedh K. Hartmann's procedure in rectal cancer: a population-based study of postoperative complications. Int J Colorectal Dis 2015; 30: 181-186.
Jörgren F, Johansson R, Arnadottir H, Lindmark G. The importance of rectal washout for the oncological outcome after Hartmann's procedure for rectal cancer: analysis of population-based data from the Swedish Colorectal Cancer Registry. Tech Coloproctol 2017; 21: 373-381.
Smedh K, Sverrisson I, Chabok A, Nikberg M; HAPIrect Collaborative Study Group. Hartmann's procedure vs abdominoperineal resection with intersphincteric dissection in patients with rectal cancer: a randomized multicentre trial (HAPIrect). BMC Surg 2016; 16: 43.
Frye JN, Carne PW, Robertson GM, Frizelle FA. Abdominoperineal resection or low Hartmann's procedure. ANZ J Surg 2004; 74: 537-540.
Molina Rodriguez JL, Flor-Lorente B, Frasson M, García-Botello S, Esclapez P, Espi A et al. Low rectal cancer: abdominoperineal resection or low Hartmann resection? A postoperative outcome analysis. Dis Colon Rectum 2011; 54: 958-962.
Tøttrup A, Frost L. Pelvic sepsis after extended Hartmann's procedure. Dis Colon Rectum 2005; 48: 251-255.
Ortiz H, Wibe A, Ciga MA, Kreisler E, Garcia-Granero E, Roig JV et al.; Spanish Rectal Cancer Project. Multicenter study of outcome in relation to the type of resection in rectal cancer. Dis Colon Rectum 2014; 57: 811-822.
Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A et al.; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29(Suppl 4): iv263.
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B et al. Colorectal cancer. Lancet 2010; 375: 1030-1047.
Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012; 13: 1152-1160.
Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24: 668-674.
Cercek A, Goodman KA, Hajj C, Weisberger E, Segal NH, Reidy-Lagunes DL et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw 2014; 12: 513-519.
Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†. Ann Oncol 2015; 26: 1722-1728.
Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol 2018; 4: e180071.
Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C et al.; ICBP Module 1 Working Group. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011; 377: 127-138.
De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D et al.; EUROCARE-5 Working Group. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014; 15: 23-34.